Compare CSV & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSV | GOSS |
|---|---|---|
| Founded | 1991 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 678.1M | 796.2M |
| IPO Year | 1996 | 2019 |
| Metric | CSV | GOSS |
|---|---|---|
| Price | $44.13 | $2.52 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $59.00 | $8.60 |
| AVG Volume (30 Days) | 77.2K | ★ 5.0M |
| Earning Date | 02-25-2026 | 11-05-2025 |
| Dividend Yield | ★ 1.02% | N/A |
| EPS Growth | ★ 38.46 | N/A |
| EPS | ★ 3.09 | N/A |
| Revenue | ★ $409,658,000.00 | $44,051,000.00 |
| Revenue This Year | $3.81 | N/A |
| Revenue Next Year | $3.37 | $6.41 |
| P/E Ratio | $14.24 | ★ N/A |
| Revenue Growth | ★ 1.07 | N/A |
| 52 Week Low | $35.51 | $0.76 |
| 52 Week High | $49.41 | $3.87 |
| Indicator | CSV | GOSS |
|---|---|---|
| Relative Strength Index (RSI) | 58.78 | 38.33 |
| Support Level | $42.92 | $2.44 |
| Resistance Level | $44.62 | $2.69 |
| Average True Range (ATR) | 1.27 | 0.21 |
| MACD | 0.16 | -0.05 |
| Stochastic Oscillator | 82.73 | 17.00 |
Carriage Services Inc is a provider of funeral and cemetery services and merchandise in the United States. It operates in two business segments: The Funeral Home Operations segment offers burial, cremation, and consultation services; removes and prepares remains; sells caskets, urns, and related funeral merchandise; and enables the use of funeral home facilities for visitation, remembrance, and transportation services. The Cemetery Operations segment provides services, such as mausoleum spaces and niches, private estates, lawn crypt gardens, traditional single burial gravesites, and burial vaults. The majority of revenue is derived from The Funeral Home Operations segment.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.